A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Types 1 and X

Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Types 1 and X

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs ACE 083 (Primary)
  • Indications Charcot-Marie-Tooth disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Acceleron Pharma
  • Most Recent Events

    • 03 Aug 2017 According to an Acceleron Pharma media release, the company expects to report results from all dose-escalation cohorts in part 1 by the end of 2018.
    • 01 Aug 2017 According to an Acceleron Pharma media release, first patient has been treated in this study.
    • 25 Apr 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top